EU steers clear of Aduhelm as a bigger headache threatens
Aduhelm’s likely EU rejection comes amid a key senior executive departure and federal inquiry, and the drug now faces a crucial Medicare decision.
The heat is on Gilead as Tropics readout nears
Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.
Esmo 2021 – Opdivo’s glimmer of hope in front-line head and neck cancer
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
